160 related articles for article (PubMed ID: 36438803)
1. Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets.
Blas-García A; Cubero FJ
Front Pharmacol; 2022; 13():1072353. PubMed ID: 36438803
[No Abstract] [Full Text] [Related]
2. Non-alcoholic fatty liver and the gut microbiota.
Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
[TBL] [Abstract][Full Text] [Related]
3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
4. Diet and gut microbiome in fatty liver and its associated liver cancer.
Pan Y; Zhang X
J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
[TBL] [Abstract][Full Text] [Related]
5. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications.
Okubo H; Kushiyama A; Nakatsu Y; Yamamotoya T; Matsunaga Y; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Asano T
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297626
[TBL] [Abstract][Full Text] [Related]
6. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
7. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.
Kobayashi T; Iwaki M; Nakajima A; Nogami A; Yoneda M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232990
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
Chu H; Williams B; Schnabl B
Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
10. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
Jennison E; Byrne CD
Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
[TBL] [Abstract][Full Text] [Related]
11. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.
Svegliati-Baroni G; Patrício B; Lioci G; Macedo MP; Gastaldelli A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823659
[TBL] [Abstract][Full Text] [Related]
12. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Jayakumar S; Loomba R
Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome and nonalcoholic fatty liver diseases.
Zhu L; Baker RD; Baker SS
Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
[TBL] [Abstract][Full Text] [Related]
14. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
[TBL] [Abstract][Full Text] [Related]
16. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
17. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
18. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
Ji Y; Yin Y; Sun L; Zhang W
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
[TBL] [Abstract][Full Text] [Related]
19. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
